Taihe Group, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TIHE research report →
Company
Taihe Group, Inc. does not have significant operations. Previously, it was operated as commercial laboratory and provided predictive chemosensitivity and immunotherapy predictive tests on biopsy tissues and other oncological laboratory testing services and products.
- CEO
- Yan Ping Sheng
- IPO
- 1998
- Employees
- 3
- HQ
- Scottsdale, AZ, US
Price Chart
Valuation
- Market Cap
- $71.85M
- P/E
- -1428.57
- P/S
- 0.00
- P/B
- -1428.57
- EV/EBITDA
- -1635.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.81%
- ROIC
- 2107.72%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-43,967 · -50.47%
- EPS
- $-0.00 · 99.99%
- Op Income
- $-43,967
- FCF YoY
- -43.33%
Performance & Tape
- 52W High
- $3.30
- 52W Low
- $1.00
- 50D MA
- $1.00
- 200D MA
- $2.51
- Beta
- 1.23
- Avg Volume
- 0
Get TickerSpark's AI analysis on TIHE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TIHE Coverage
We haven't published any research on TIHE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TIHE Report →